Synmosa Biopharma Corporation is a pharmaceutical company engaged in the research, development, and manufacturing of solid, semi-solid, and liquid dosage forms, including tablets, capsules, granules, dry powder inhalers, ointments, sprays, and injectables. The company also produces medical devices, cosmetics, and functional foods. Its manufacturing capabilities are supported by five technology platforms: effervescent tablet technology, HFA metered-dose inhaler technology, nasal spray technology, sex hormone technology, and granules technology. The company operates a dedicated hormone manufacturing facility that passed PIC/S GMP inspection in 2011. Synmosa Biopharma serves the healthcare sector with products for gastrointestinal disorders and other therapeutic areas, including a recently launched triple-mechanism drug for constipation. The company reports strong revenue growth driven by new product launches and international collaborations.

Summarised from the company's own disclosures

Industry Drug Manufacturers - Specialty & Generic Homepage synmosa.com.tw
Sector Healthcare IR page synmosa.com.tw/InvestorRelations
Tags
pharmaceutical manufacturing, solid dosage forms, liquid dosage forms, medical devices, cosmetics, functional foods, effervescent tablets, metered-dose inhalers, nasal sprays, sex hormones, granules, gastroenterology, Effervescent Tablet Technology, HFA MDI Technology, Nasal Spray Technology Platform, Sex Hormone Technology, Granules Technology
Press page —

Metrics

Valuation  
Market cap NT$ 13.788B
Market cap (USD) $ 418.492M
P/E 16.31
PEG 17.34
P/BV 1.57
P/S 1.87
P/OCF 17.66
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.3%
ROI 9.4%
ROIC 6.9%
Profit margin 13.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 0.94%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 6.189B 5.55B 5.14B 4.386B 3.235B 3.038B 2.68B 2.363B 1.861B 1.865B 1.776B 1.476B 1.249B 1.067B 927.806M 824.706M
Net profit 821.849M 684.683M 594.832M 799.091M 303.86M 638.112M 47.09M 430.899M 4.688M 166.65M 31.541M 110.267M 62.926M 91.862M -22.578M 32.024M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 32.4 — — — — — — — — — — — — — — —
P/S 2.63 — — — — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Synmosa Biopharma Corporation (ticker 4114.TWO), listed in Taiwan.

ETFs Holding Synmosa Biopharma Corporation

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 48,058 $ 38.857K Nov 16, 2026
DEXC 0.01% 44,125 $ 36.872K Nov 12, 2026
DFEV 0.01% 267,646 $ 223.651K Nov 12, 2026
DFSE 0.01% 56,757 $ 47.427K Nov 12, 2026
DFEM 0.01% 618,491 $ 516.824K Nov 12, 2026
DFAE 0.00% 395,194 $ 330.232K Nov 12, 2026
DFAX 0.00% 374,504 $ 312.943K Nov 12, 2026